Vascular Targeted Photodynamic therapy with WST11 for T1a Renal Tumour

• Research type

  Research Study

• Full title

  Vascular Targeted Photodynamic therapy with WST11 for T1a Renal Tumours. PHASE I histological follow up trial

• IRAS ID

  87249

• Contact name

  Mark Sullivan

• Eudract number

  2011-003311-27

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  As a result of the increased use of abdominal imaging (CT, MRI, Ultrasound), new renal cancers are increasingly diagnosed when they are small (<4cm maximum diameter). These tumours are currently best managed by nephron-sparing surgery. A safer alternative to surgery would be a very attractive option, particularly for elderly patients with significant co-morbidity. Vascular Targeted Photodynamic therapy (VTP) with the Vascular Occluding Agent (VOA) WST11, may offer an alternative, providing tumour destruction via a minimally invasive approach.In this investigation, we plan to use the WST11 VTP procedure to treat a predetermined small renal tumour targets. Patients will be given a general anaesthetic, to ensure immobility, and prevent discomfort during treatment sessions. Treated patients will then undergo surgical resection of their tumours, and the accuracy and reliability of tissue death with VTP will be assessed histologically. The aim of this proof of concept study is to demonstrate whether this modality has potential for a clinical role in the treatment of oncological kidney disease, either as an alternative to surgery, or where surgery is not feasible. This research will be funded by the University of Oxford and a grant from STEBA BIOTECH and will be recruiting in the Oxford region.

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  12/SC/0281

• Date of REC Opinion

  3 Aug 2012

• REC opinion

  Further Information Favourable Opinion